-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Neutral on Arcturus Therapeutics, Lowers Price Target to $7

Benzinga·01/06/2026 18:38:50
語音播報
Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and lowers the price target from $9 to $7.